A group of direct buyers of the cholesterol drug Niaspan scored a victory on Wednesday when a Pennsylvania federal judge approved their bid to move forward as a class with a pay-for-delay antitrust suit against Teva Pharmaceuticals Industries Ltd. and AbbVie Inc…
…
Read this piece in its entirety at Law360.